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| INTRODUC TI ON
Lung cancer is the most common cause of cancer deaths worldwide. 1 Mutations of the epidermal growth factor receptor (EGFR) gene are common drivers of non-small cell lung cancer (NSCLC), 2 and EGFR tyrosine kinase inhibitors (TKIs) are considered the best choice for first- as a checkpoint in regulation of the immune system by inhibiting T cell activation, thereby suppressing autoimmunity and promoting autoimmune tolerance. 4 Many types of tumor cells express PD-L1, and inhibition of the binding of PD-L1 to PD-1 has been found to enhance T cell responses in vitro as well as to have an antitumor effect in preclinical studies. 5 Immune-checkpoint inhibitors that interfere with the interaction between PD-1 and PD-L1 have recently been found to be superior to docetaxel in terms of both overall survival and tolerability for the treatment of NSCLC, although a durable benefit is observed in only ~20% of patients and some individuals may experience unprecedented immune-related adverse events. [6] [7] [8] [9] Subgroup analysis has suggested that inhibition of the PD-1-PD-L1 axis is less effective in NSCLC patients positive for EGFR mutations than in those wild type for EGFR. 7, 10 12 We have now examined whether EGFR signaling might inhibit surface MHC-I expression, resulting in loss of immunogenicity, in EGFR mutation-positive NSCLC. We found that inhibition of a specific EGFR signaling pathway by targeted agents was able to increase MHC-I expression in such NSCLC cells.
| MATERIAL AND ME THODS

| Human NSCLC cell lines and reagents
The PC9 cell line was kindly provided by Dr. Hayata (Tokyo Medical University). The PC9GR cell line was previously described. 13 The cell 
| Flow cytometry
Cells were dissociated and collected with the use of Accutase cell- 
| Immunoblot analysis
| Immunohistochemistry
Immunohistochemical staining was performed as previously described. 14 
| Patients and tumor specimens
The use of human tissue was in accordance with the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Kindai University. Tumor samples were obtained from NSCLC patients with EGFR mutations both before initiation of EGFR-TKI therapy as well as after disease progression during the treatment.
| Statistical analysis
Quantitative data are presented as means + SE and were compared with the two-sided unpaired Student's t test. The analysis was performed with the use of GraphPad Prism v.7 software (GraphPad Inc., La Jolla, CA, USA). A P value < 0.05 was considered statistically significant.
| RE SULTS
| EGFR mutated NSCLC cells tended to show lower expression level of HLA-B compared to EGFR wild type NSCLC cells
Epidermal growth factor receptor is a transmembrane protein that is 
| Role of the MEK-ERK pathway in induction of MHC-I expression by EGFR inhibition
The phosphatidylinositol 
| Down-regulation of phospho-EGFR and phospho-ERK associated with up-regulation of MHC-I in tumor tissue
To 
| D ISCUSS I ON
Epidermal growth factor receptor is a receptor tyrosine kinase 
15,18
Although the development of PD-1-PD-L1 inhibitors has improved treatment outcome for NSCLC patients, the presence of EGFR mutations, which have been identified in ~40% to 60% of lung adenocarcinomas in East Asia, 19 has been associated with a low response rate to such drugs. 10, 11 Antibodies to PD-1 or to PD-L1 relieve effec- Epidermal growth factor receptor-TKIs are considered the best choice for first-line treatment of advanced EGFR-mutated NSCLC, 22 but treated individuals eventually develop resistance to these drugs, most often as a result of the emergence of a secondary T790M mutation of EGFR. Osimertinib was designed to overcome such resistance conferred by the T790M mutation and has been approved and now widely adopted for treatment of NSCLC positive for this mutation. 23 On the other hand, we previously found that, among EGFR-TKI-resistant patients, those negative for T790M tended to show a more favorable response to the PD-1-targeted antibody nivolumab compared with those positive for T790M. 24 The results of the present and previous studies suggest that EGFR pathway activation is maintained in T790M-positive tumors that generally show a durable response to osimertinib and may lead to suppression of MHC-I expression. 18 We found that osimertinib overcomes such suppression of MHC-I in T790M-positive PC9GR and H1975 cells. 
